3SBio Inc. Announces Unaudited Second Quarter 20...(income to our adjustedstatements of inco...),Health

    (1). To exclude share-based compensation expenses from its non-GAAP
         measures primarily because they are non-cash expenses that the
         Company does not believe are reflective of ongoing operating results.

    (2). To exclude the impact caused by the impairment and disposal of
         available-for-sale securities, which is one-off in nature.



                          3SBio Inc. and subsidiaries
              Unaudited quarterly consolidated statements of income
     (expressed in thousands, except per share , per ADS and other share and
                                    ADS data)
    Six Months Ended June 30,2008
                                        GAAP         GAAP         Adjustment
                                         RMB          US$                RMB
    Net Revenues:
    EPIAO                             72,594       10,583                 --
    TPIAO                             31,476        4,589                 --
    Intefen                            2,392          349                 --
    Inleusin                             378           55                 --
    Iron                               3,455          504                 --
    Export                             4,702          686                 --
    Others                                34            5                 --

    Total net revenues               115,031       16,771
    Cost of revenues                 (10,196)      (1,487)             149(1)

    Gross profit                     104,835       15,284

    Operating expenses
    Research and development
     costs                            (5,796)        (845)             205(1)
    Sales, marketing and
     distribution expenses           (52,181)      (7,608)             394(1)
    General and administrative
     expenses                        (17,480)      (2,548)           1,433(1)

    T
'/>"/>
SOURCE  3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Related medicine news :

1. 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
2. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
3. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
4. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
5. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
7. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. Leading Medical Developer Announces Plans for Texoma Medical Plaza
10. iMedX Announces Investment of $13M From RFE Investment Partners
11. Health Market Science Announces Commercial Release of CompleteSpend V2.5